



## Carbapenem-Resistant Organisms (CRO) as Leading Cause of Hospital Associated Infections

Guest Editor:

**Dr. Marianna Meschiari**

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, University of Modena and Reggio Emilia, Via del Pozzo 71, 41122 Modena, Italy

Deadline for manuscript submissions:

**closed (31 January 2023)**

### Message from the Guest Editor

Dear Colleagues,

Healthcare-associated infections (HAIs) continue to be a major global health challenge, particularly because of the increasing prevalence of multidrug-resistant organisms and their ability to cause outbreaks in the hospital setting. Antimicrobial resistance has deleterious implications both for patients (in terms of mortality, morbidity, and health-related quality of life), as well as for the healthcare system (economic costs).

Three species in particular pose the greatest global concern: carbapenemase-producing or carbapenem-resistant *Enterobacterales*, carbapenem-resistant *Pseudomonas aeruginosa*, and carbapenem-resistant *Acinetobacter baumannii*.

These Carbapenem-resistant organisms (CROs) represent a particular threat in hospitals, nursing homes, and among patients whose care requires devices such as ventilators and blood catheters.

In response to the publication of the list of priority pathogens by the WHO in 2017, new antibiotic drugs have been developed and were later approved to provide new therapeutic options against these resistant pathogens.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi